Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

Delayed Quote. Delayed  - 09/26 10:01:56 pm
79.52 USD   -2.02%
09/24 ELI LILLY AND : William Conner House
09/19DJSanofi Files Suit Against Merck
09/19 ELI LILLY AND : Everence Capital Management Inc Lowers stake in Eli ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

 
   By Saabira Chaudhuri 
 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND CO
09/24 ELI LILLY AND : William Conner House
09/21 ABBVIE : Researchers say there are no benefits of testosterone treatments for me..
09/19DJSanofi Files Suit Against Merck
09/19 ELI LILLY AND : Everence Capital Management Inc Lowers stake in Eli Lilly and Co..
09/16 ELI LILLY AND : CHMP Recommends Approval of Lilly's Olaratumab, in Combination w..
09/16 ELI LILLY AND : Assigned Patent
09/15 ELI LILLY AND : An Application for the Trademark "VIEW" Has Been Filed by Eli Li..
09/15 ELI LILLY AND : Trademark Application for "SHINE" Filed by Eli Lilly
09/15 ELI LILLY AND : Crystallization plate provides clues on protein structure aboard..
09/15 ELI LILLY AND : An Application for the Trademark "SILAPUR" Has Been Filed by Eli..
More news
Sector news : Pharmaceuticals - NEC
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 Cerecor nabs rights to epilepsy candidate from Eli Lilly
09/23 Spotlight On Axovant After Lundbeck's Alzheimer's Failure
09/23 ELI LILLY JANUARY 2017 OPTIONS : An Iron Condor Idea
09/22 Biontech Deal Sees Roche Bet On mRNA
09/20 Janney sees many suitors for Clovis; shares move higher, again, in post marke..
Advertisement
Financials ($)
Sales 2016 21 183 M
EBIT 2016 4 751 M
Net income 2016 3 316 M
Debt 2016 2 745 M
Yield 2016 2,53%
P/E ratio 2016 27,96
P/E ratio 2017 22,02
EV / Sales 2016 4,36x
EV / Sales 2017 4,15x
Capitalization 89 588 M
More Financials
Chart ELI LILLY AND CO
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 97,5 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John C. Lechleiter Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer
Jan M. Lundberg Executive Vice President-Science & Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO-3.68%89 588
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results